Paul A. Volberding, MD

University of Chicago, BA, 1967-1971, Biology
University of Minnesota, MD, 1971-1975, Medicine
University of Utah Medical Center, Residency, 1975-1978, Internal Medicine
University of California San Francisco, Fellow, 1978-1981, Hematology/Oncology

• 1968-1971
  Virology Laboratory Assistant, Dr. Marc Beem, University of Chicago
• 1971-1975
  University of Minnesota School of Medicine
  Avian type C virus receptor research, Dr. Charles Moldow
• 1975-1978
  Medicine Internship and Residency, University of Utah Medical Center, Salt Lake City
• 1978-1979
  Clinical Fellow in Hematology/Oncology, University of California, San Francisco
  Clinical research conducted with Dr. Michael Friedman on therapy of hepatic tumors
• 1979-1981
  Research Fellow in Hematology/Oncology, University of California, San Francisco
  Research conducted in the laboratory of Dr. Jay A. Levy studying mechanisms controlling infection with xenotropic type C retroviruses
• 1981-1986
  Assistant Professor of Medicine, University of California, San Francisco
• 1981-present
  Chief, Medical Oncology Division, San Francisco General Hospital
• 1984-present
  Director, AIDS Program, San Francisco General Hospital
• 1986-1990
  Associate Professor of Medicine, University of California, San Francisco
• 1988-present
  Director, Center for AIDS Research, University of California, San Francisco
• 1990-present
  Professor of Medicine, University of California, San Francisco
• 1994-present
  Full Member, Cancer Center, University of California, San Francisco
• 1997
  Program Leader, HIV Malignancies Research Program, UCSF Comprehensive Cancer Center
• 2001-present
  Vice Chair, Department of Medicine, University of California, San Francisco
• 2001-present
  Chief of the Medical Service, San Francisco Veterans Affairs Medical Center

• 1986-1987
  National Academy of Sciences (Institute of Medicine) AIDS Policy Review Steering Committee
• 1986-1987
  American Medical Association AIDS Panel
• 1986-1988
  NIH AIDS Drug Selection Committee Member
• 1986-1988
  National Institutes of Allergy and Infectious Disease AIDS Clinical Trials Group Executive Committee
• 1987-1990
  National Academy of Sciences (Institute of Medicine) AIDS Activities Oversight Committee
• 1990-1992
  International AIDS Society, President
• 1992-1993
  Co-chair Institute of Medicine Round Table on AIDS Drug and Vaccine Development
• 1993-present
  Founder and Board Chair, International AIDS Society - USA, Inc.
• 1994-present
  National Policy Advisory Board for the HIV Cost and Services Utilization Study, RAND
• 1997-present
  HIV Research Agenda Committee, AIDS Clinical Trials Group
• 1998-present
  Interim Review Committee, ACTG 372
• 1998-present
  Interim Review Committee, ACTG 368
• 1998-present
  Center for AIDS Research Directors' Group, Chair
• 1999-present
  Institute of Medicine

• Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin, R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, Balfour HH, Spector SA. Volberding PA, Pettinelli C. Anderson J, and the AIDS Clinical Trials Group. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Annals of Internal Medicine 1990; 112:727-737.
• Kahn JO, Allan JD, Hodges TL, Kaplan LD, Arri CJ, Fitch HF, Izu AE, Mordenti J, Sherwin SA, Groopman JE, Volberding PA. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Annals of Internal Medicine 1990;112: 254-261.
• Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA, Abrams DI, and the San Francisco County Community Consortium. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. N Engl J Med 1190; 323:769-775.
• Hodges TL, Kahn JO, Kaplan LD, Groopman JE, Volberding PA, Amman AJ, Arri CJ, Bouvier LM, Mordenti J, Izu AE, Allan JD. Phase I study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother 1991; 35:2580-2586.
• Lagakos SW, Fischl MA, Stein DS, Lim L, Volberding PA. Effects of zidovudine therapy in minority and other subpopulations with Early HIV infection. JAMA 1992; 266:2709-2712.
• Kahn JO, Lagakos SW, Richman DD, Pettinelli C, Liou S-H, Brown M, Volberding PA, Crumpacker CS, Beall G, Sacks HS, Merigan TC, Beltanfady M, Smaldon L, Dolin R, and the NIAID AIDS Clinical Trials Group. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327:581-587.
• Fischl MA, Frown SE, O'Boyle KP, Mitsuyasu R, Miles S, Wernz JC, Volberding PA, Kahn JO, Groopman JE, Feinberg J, Woody M, and the AIDS Clinical Trials Group. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. JAIDS 1993; 6:259-264.
• Koch MA, Volberding PA, Lagakos SW, Booth DK, Pettinelli C, Myers MW. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.52x10 9/L or less. Arch Intern Med 1992; 152:2286-2292.
• Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993; 118:674-680.
• Collier AC, Coombs RW, Fischl MA, Skolnick PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, Henrard DR, Weller S, Corey L. Combination therapy with zidovudine and didanosine compared to zidovudine alone in HIV-1 infection. Ann of Int Med 1993; 119:76-793.
• Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. The J of Inf Dis 1993; 169:28-36.
• Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA. Quality-of-life evaluation of zidovudine in asymptomatic human immunodeficiency virus type 1 (HIV) infection: Q-TWiST analysis of a controlled trial in persons with fewer than 500 CD4+/mm3 N Engl J Med 1994; 330:738-743.
• Volberding PA, Graham NMH. Initiation of antiretroviral therapy is HIV infection: a review of interstudy consistencies. JAIDS 1994:7(Suppl.2.):S12-S23.
• Kaplan LD, Shiramizu B., Herndier B., Hahn J, Meeker TC, Ng V, Volberding PA, McGrath MS. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus associated non-Hodkin's lymphoma: Identification of a subgroup with favorable clinical outcome. Blood 1995: 85(7):1727-1735.
• Jacobson MA, De Gruttola V, Reddy M, Arduino J-M, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, Soeiro R, Volberding PA. The predictive value of early changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS, 1995, 9:727-734.
• Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng T-C, Fischl MA, Collier AC, Phair JP, Hirsch MS, Hardy WD, Balfour HH, Reichman RC, for the AIDS Clinical Trials Group. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. NEJM 1995, 333:7:401-407.
• Carpenter CJC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1996; recommendations of an international panel. JAMA, 1996, 276:2:146-154.
• Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DJ, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1997, updated recommendations of the International AIDS Society - USA Panel. JAMA, 277:24:1962-1969.
• Volberding PA, Deeks S. Antiretroviral therapy for HIV infection: promises and problems. JAMA, 279:17:1343-1344.
• Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DJ, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1998, updated recommendations of the International AIDS Society - USA Panel. JAMA, 280:1:78-86.